Ascendis Pharma announced that the FDA has accepted its New Drug Application for TransCon CNP, a treatment for children with achondroplasia, for priority review.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

Shares of Ascendis Pharma AS (NASDAQ:ASND) rose 5.8% after the U.S. Food and Drug Administration (FDA) accepted the company’s ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide ...

COPENHAGEN - Ascendis ... of TransCon CNP as a treatment for children with achondroplasia, aiming to improve their growth outcomes and overall quality of life. Ascendis Pharma plans to further ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide ...

Ascendis Pharma, a biopharmaceutical company, focuses on developing new therapies using its TransCon technology platform. The company’s Chief Medical Officer, Dr. Aimee Shu, expressed optimism about ...

Transcon CNP (to treat achondroplasia), that was submitted for FDA approval in Q1 and could be launched in 2026." Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?